NZ592041A - Compositions and methods for topical application and transdermal delivery of botulinum toxins - Google Patents

Compositions and methods for topical application and transdermal delivery of botulinum toxins

Info

Publication number
NZ592041A
NZ592041A NZ592041A NZ59204105A NZ592041A NZ 592041 A NZ592041 A NZ 592041A NZ 592041 A NZ592041 A NZ 592041A NZ 59204105 A NZ59204105 A NZ 59204105A NZ 592041 A NZ592041 A NZ 592041A
Authority
NZ
New Zealand
Prior art keywords
gly
positively charged
botulinum toxin
transdermal delivery
integer
Prior art date
Application number
NZ592041A
Other languages
English (en)
Inventor
Jacob M Waugh
Michael D Dake
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of NZ592041A publication Critical patent/NZ592041A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
NZ592041A 2004-03-03 2005-03-03 Compositions and methods for topical application and transdermal delivery of botulinum toxins NZ592041A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55001504P 2004-03-03 2004-03-03

Publications (1)

Publication Number Publication Date
NZ592041A true NZ592041A (en) 2012-12-21

Family

ID=34919562

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592041A NZ592041A (en) 2004-03-03 2005-03-03 Compositions and methods for topical application and transdermal delivery of botulinum toxins

Country Status (24)

Country Link
US (2) US8404249B2 (https=)
EP (3) EP1729821B1 (https=)
JP (1) JP5095388B2 (https=)
KR (3) KR101330775B1 (https=)
CN (2) CN102357062B (https=)
AU (1) AU2005218665A1 (https=)
BR (1) BRPI0508410B8 (https=)
CA (1) CA2558408C (https=)
CR (1) CR8602A (https=)
CY (1) CY1120816T1 (https=)
DK (3) DK1729821T3 (https=)
ES (3) ES2554821T3 (https=)
HU (1) HUE025656T2 (https=)
IL (4) IL177816A (https=)
LT (1) LT2985039T (https=)
MX (2) MX345724B (https=)
NO (1) NO20064490L (https=)
NZ (1) NZ592041A (https=)
PL (1) PL2985039T3 (https=)
PT (3) PT2656859E (https=)
SG (3) SG150568A1 (https=)
SI (3) SI1729821T1 (https=)
TR (1) TR201815364T4 (https=)
WO (1) WO2005084410A2 (https=)

Families Citing this family (109)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ćƒ«ćƒćƒ³ć‚¹ ć‚»ćƒ©ćƒ”ćƒ„ćƒ†ć‚£ćƒƒć‚Æć‚¹ ć‚¤ćƒ³ć‚Æļ¼Žļ¼²ļ½…ļ½–ļ½ļ½Žļ½ƒļ½… ļ¼“ļ½ˆļ½…ļ½’ļ½ļ½ļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½“ļ¼Œļ¼©ļ½Žļ½ƒļ¼Ž å¤šęˆåˆ†ē”Ÿē‰©å­¦ēš„č¼øé€ć‚·ć‚¹ćƒ†ćƒ 
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
KR20050045946A (ko) 2002-06-25 2005-05-17 ģ• ķ¬ėŸ­ģŠ¤ ė””ė””ģ—ģŠ¤ ķ”¼ķ‹°ģ™€ģ“ ė¦¬ėÆøķ‹°ė“œ ė¹„ģ •ģ§ˆ ģ•½ķ•™ģ  ģ”°ģ„±ė¬¼ģ„ ģ“ģš©ķ•œ ź²½ķ”¼ģ „ė‹¬ģ†ė„ģ˜ ģ œģ–“
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmƩtica y farmacƩutica
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
JP2007527431A (ja) * 2004-03-03 2007-09-27 ćƒ«ćƒćƒ³ć‚¹ ć‚»ćƒ©ćƒ”ćƒ„ćƒ†ć‚£ćƒƒć‚Æć‚¹ å±€ę‰€ēš„čØŗę–­åŠć³ę²»ē™‚ē”Ø恮č¼øé€ć®ćŸć‚ć®ēµ„ęˆē‰©åŠć³ę–¹ę³•
BRPI0508410B8 (pt) 2004-03-03 2021-05-25 Revance Therapeutics Inc composiƧƵes e mĆ©todos para a aplicaĆ§Ć£o tĆ³pica e liberaĆ§Ć£o transdĆ©rmica de toxinas botulĆ­nicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
ZA200707352B (en) * 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2013201374B2 (en) * 2005-03-03 2015-05-21 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2007039825A2 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
KR20130114229A (ko) * 2005-06-03 2013-10-16 ģ• ķ¬ėŸ­ģŠ¤ ė””ė””ģ—ģŠ¤ ķ”¼ķ‹°ģ™€ģ“ ė¦¬ėÆøķ‹°ė“œ ź²½ķ”¼ ģ•½ė¬¼ ģ „ė‹¬ ė°©ė²• ė° ģ”°ģ„±ė¬¼
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
WO2007119099A2 (en) * 2005-09-12 2007-10-25 Foamix Ltd. Apparatus and method for releasing a measure of content from a plurality of containers
CN103126971A (zh) * 2005-11-17 2013-06-05 é›·ę–‡ę–Æę²»ē–—å…¬åø 减少非ęƒē“ č›‹ē™½č“Øēš„肉ęÆ’ę†čŒęƒē“ ē»„合ē‰©å’Œå…¶å±€éƒØę–½ē”Ø及透ēš®é€’é€ę–¹ę³•
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
KR102110379B1 (ko) 2005-12-01 2020-05-14 ģœ ė‹ˆė²„ģ‹œķ‹° ģ˜¤ėøŒ ė©”ģ‚¬ģø„ģ„øģø  ė”œģ›° ė³“ķˆ“ė¦¬ėˆ” ė‚˜ė…øģ—ė©€ģ ¼
US8273867B2 (en) * 2006-02-10 2012-09-25 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
CN101074935B (zh) * 2006-05-19 2011-03-23 ęø…华大学 ęŽ¢ęµ‹å™Øé˜µåˆ—åŠč®¾å¤‡
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
CN102988995A (zh) * 2006-12-29 2013-03-27 é›·ę–‡ę–Æę²»ē–—å…¬åø ē”Øęŗč‡Ŗhiv-tatēš„å¤šč‚½ē‰‡ę®µēس定ēš„肉ęÆ’ę†čŒęƒē“ ēš„ē»„合ē‰©åŠå…¶å±€éƒØę–½ē”Ø和透ēš®é€’送ēš„ę–¹ę³•
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc MolĆ©culas de transporte que utilizam polipeptĆ­deos hiv-tat de sequĆŖncia inversa.
RU2526904C2 (ru) * 2007-05-11 2014-08-27 Š”Š·Šµ Š‘Š¾Ń€Š“ ŠžŃ„ Š ŠøŠ“Š¶ŠµŠ½Ń‚с ŠžŃ„ Š”Š·Šµ Š®Š½ŠøŠ²Ń‘рсŠøтŠø ŠžŃ„ ŠŠµŠ±Ń€Š°ŃŠŗŠ° ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š“Š»Ń Š“Š¾ŃŃ‚Š°Š²ŠŗŠø Š±ŠµŠ»ŠŗŠ¾Š² Šø Š¼ŠµŃ‚Š¾Š“ы Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
CN101765423B (zh) 2007-05-31 2014-08-06 安ē‰¹é‡Œå„„公åø ę øé…øēŗ³ē±³ē²’子和其ē”Ø途
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009056991A2 (en) * 2007-09-04 2009-05-07 Foamix Ltd. Device for delivery of a foamable composition
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulĆ­nica
US20120014894A1 (en) * 2008-12-31 2012-01-19 Revance Therapeutics, Inc. Compositions and Methods for Treating Hyperpigmentation
HUE037595T2 (hu) * 2008-12-31 2018-09-28 Revance Therapeutics Inc InjektĆ”lhatĆ³ botulinum toxin kĆ©szĆ­tmĆ©nyek
EP2413947B1 (en) 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482838A4 (en) * 2009-09-30 2013-04-10 Toxcure Inc USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011049954A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
SI2490986T1 (sl) * 2009-10-21 2018-12-31 Revance Therapeutics, Inc. Metode in sistemi za prečiŔčenje nekompleksiranega nevrotoksina botulina
US20110106021A1 (en) * 2009-10-30 2011-05-05 Revance Therapeutics, Inc. Device and Method for Topical Application of Therapeutics or Cosmetic Compositions
CA2788656A1 (en) * 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
BR112012021943B1 (pt) 2010-03-03 2021-09-28 3M Innovative Properties Company MĆ©todo de separaĆ§Ć£o de uma espĆ©cie biolĆ³gica-alvo de um fluido
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
LT2661276T (lt) * 2011-01-07 2017-12-11 Revance Therapeutics, Inc. PavirÅ”inio naudojimo kompozicija, apimanti botulino toksiną ir dažą
BR112013018918A2 (pt) * 2011-01-24 2016-10-04 Anterios Inc composiƧƵes de nanopartƭculas
US8791072B2 (en) * 2011-02-28 2014-07-29 Neuro-Ophthalmix, Llc Modulating neuromuscular junction density changes in botulinum-toxin treated tissue
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
EP2734224A1 (en) * 2011-07-20 2014-05-28 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
US20130251770A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of Treatment of Wrinkles Using Topical Chemodenervating Agents
CN104781271B (zh) 2012-08-20 2018-07-06 加利ē¦å°¼äŗšå¤§å­¦č‘£äŗ‹ä¼š å…·ęœ‰ē”Ÿē‰©åÆ逆ēš„åŸŗ团ēš„多ę øč‹·é…ø
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
JP2016525569A (ja) 2013-07-30 2016-08-25 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ć€ć‚¤ćƒ³ćƒ†ćƒ¬ć‚Æćƒćƒ„ć‚¢ćƒ«ć€ćƒ—ćƒ­ćƒ‘ćƒ†ć‚£ćƒ¼ć€ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆć€ćƒŖ惟惆惃惉ļ¼§ļ½Œļ½ļ½˜ļ½ļ½“ļ½ļ½‰ļ½”ļ½ˆļ½‹ļ½Œļ½‰ļ½Žļ½… ļ¼©ļ½Žļ½”ļ½…ļ½Œļ½Œļ½…ļ½ƒļ½”ļ½•ļ½ļ½Œ ļ¼°ļ½’ļ½ļ½ļ½…ļ½’ļ½”ļ½™ ļ¼¤ļ½…ļ½–ļ½…ļ½Œļ½ļ½ļ½ļ½…ļ½Žļ½” ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ ē™ŗę±—éŽå¤šć®ę²»ē™‚ć®ćŸć‚ć®å±€ę‰€ē”Øēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Øę–¹ę³•
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016092365A1 (en) 2014-12-08 2016-06-16 JJSK R&D Pte Ltd Carrier molecule compositions and related methods
FR3030524B1 (fr) * 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
KR101876177B1 (ko) * 2016-02-17 2018-07-09 ź°€ķ†Øė¦­ź“€ė™ėŒ€ķ•™źµģ‚°ķ•™ķ˜‘ė „ė‹Ø ź²½ķ”¼ķˆ¬ź³¼ ė³“ķˆ“ė¦¬ėˆ” ė…ģ†Œ ķŒØģ¹˜
KR101997474B1 (ko) 2016-06-13 2019-07-09 źø°ģ“ˆź³¼ķ•™ģ—°źµ¬ģ› ģæ ģ»¤ė¹„ķˆ¬[n]ė¦“ģ„ ģ“ģš©ķ•˜ģ—¬ ģ‹ ź²½ģ „ė‹¬ė¬¼ģ§ˆģ„ ģ œģ–“ķ•˜ėŠ” ė°©ė²• ė° ģ“ģ˜ ģš©ė„
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
KR102480965B1 (ko) 2016-09-13 2022-12-26 ģ•Œė ˆź°„ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ•ˆģ •ķ™”ėœ ė¹„ė‹Øė°±ģ§ˆ ķ“ė”œģŠ¤ķŠøė¦¬ė“ ė…ģ†Œ ģ”°ģ„±ė¬¼
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
EP3624819A4 (en) 2017-05-18 2021-03-24 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
JP7227970B2 (ja) * 2017-07-21 2023-02-22 ć‚·ćƒ£ćƒ³ćƒć‚¤ćƒ†ćƒƒć‚Æ ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ å±€ę‰€ē”Øēµ„ęˆē‰©åŠć³ä½æē”Ø
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
US10918586B2 (en) * 2017-12-07 2021-02-16 Ps Therapy Ltd. Topical compositions and methods of use thereof
AU2018389104A1 (en) 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
KR102088104B1 (ko) * 2018-06-29 2020-03-11 ķ˜øģ„œėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø ź°œė§ģ“ˆ ź½ƒ ģ—ģ„¼ģ…œ ģ˜¤ģ¼ģ„ ķ¬ķ•Øķ•˜ėŠ” ģ‹ ź²½ ź·¼ģœ” ź“€ė Ø ģ§ˆķ™˜ ģ˜ˆė°© ė° ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
WO2022055927A1 (en) * 2020-09-11 2022-03-17 Ps Therapy Ltd. Topical compositions and methods of use
AU2021394765A1 (en) * 2020-12-09 2023-06-29 Dermata Therapeutics, Inc. Compositions for the treatment of skin conditions
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance

Family Cites Families (97)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (ja) * 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd ēµŒēš®åø収äæƒé€²å‰¤ćŠć‚ˆć³ć“ć‚Œć‚’å«ęœ‰ć—ć¦ćŖ悋ēš®č†šå¤–ē”Ø剤
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6986893B2 (en) 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
DE69428813T2 (de) 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmƄte til Ƅ innfƶre molekyler i cellers cytosol
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9600272D0 (en) 1996-01-06 1996-03-06 Univ Nottingham Polymers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
CN1263473A (zh) 1997-05-21 2000-08-16 利兰Ā·ę–Æ坦ē¦é’å¹“å¤§å­¦ę‰˜ē®”委员会 增加č·Øē”Ÿē‰©č†œč½¬čæēš„ē»„合ē‰©å’Œę–¹ę³•
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
EP1117720A4 (en) 1998-07-13 2001-11-14 Expression Genetics Inc POLYESTER POLY-L-LYSINE ANALOG USED AS A BIODEGRADABLE SOLUBLE GENE CONVEYOR
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000024419A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ćƒ«ćƒćƒ³ć‚¹ ć‚»ćƒ©ćƒ”ćƒ„ćƒ†ć‚£ćƒƒć‚Æć‚¹ ć‚¤ćƒ³ć‚Æļ¼Žļ¼²ļ½…ļ½–ļ½ļ½Žļ½ƒļ½… ļ¼“ļ½ˆļ½…ļ½’ļ½ļ½ļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½“ļ¼Œļ¼©ļ½Žļ½ƒļ¼Ž å¤šęˆåˆ†ē”Ÿē‰©å­¦ēš„č¼øé€ć‚·ć‚¹ćƒ†ćƒ 
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
DE60233137D1 (de) 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
DK1411978T3 (da) * 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
WO2003049772A2 (en) 2001-12-11 2003-06-19 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
EP1531859A4 (en) 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
JP2007527431A (ja) * 2004-03-03 2007-09-27 ćƒ«ćƒćƒ³ć‚¹ ć‚»ćƒ©ćƒ”ćƒ„ćƒ†ć‚£ćƒƒć‚Æć‚¹ å±€ę‰€ēš„čØŗę–­åŠć³ę²»ē™‚ē”Ø恮č¼øé€ć®ćŸć‚ć®ēµ„ęˆē‰©åŠć³ę–¹ę³•
BRPI0508410B8 (pt) 2004-03-03 2021-05-25 Revance Therapeutics Inc composiƧƵes e mĆ©todos para a aplicaĆ§Ć£o tĆ³pica e liberaĆ§Ć£o transdĆ©rmica de toxinas botulĆ­nicas
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP2266599B1 (en) 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
HK1221650A1 (en) 2017-06-09
IL237386A (en) 2017-07-31
PL2985039T3 (pl) 2019-01-31
ES2554821T3 (es) 2015-12-23
NO20064490L (no) 2006-10-03
EP2656859A2 (en) 2013-10-30
CN1946431B (zh) 2011-12-07
EP1729821A2 (en) 2006-12-13
JP5095388B2 (ja) 2012-12-12
IL177816A0 (en) 2006-12-31
ES2431610T3 (es) 2013-11-27
EP2656859B1 (en) 2015-10-21
JP2007526340A (ja) 2007-09-13
US20050196414A1 (en) 2005-09-08
KR20120091198A (ko) 2012-08-17
SI1729821T1 (sl) 2013-12-31
CN102357062A (zh) 2012-02-22
CY1120816T1 (el) 2019-12-11
HUE025656T2 (en) 2016-04-28
CA2558408C (en) 2014-11-18
DK1729821T3 (da) 2013-10-28
IL253007B (en) 2019-11-28
US8398997B2 (en) 2013-03-19
US8404249B2 (en) 2013-03-26
WO2005084410A3 (en) 2006-06-29
LT2985039T (lt) 2018-11-12
US20080107690A1 (en) 2008-05-08
KR101343411B1 (ko) 2013-12-19
IL237386A0 (en) 2015-04-30
ES2691498T3 (es) 2018-11-27
KR20070018047A (ko) 2007-02-13
DK2656859T3 (en) 2016-01-11
HK1162952A1 (zh) 2012-09-07
CR8602A (es) 2007-11-20
IL237388A (en) 2017-07-31
SG10201400339VA (en) 2014-05-29
IL177816A (en) 2015-02-26
EP2656859A3 (en) 2014-02-19
AU2005218665A1 (en) 2005-09-15
DK2985039T3 (en) 2018-11-19
CN1946431A (zh) 2007-04-11
BRPI0508410B8 (pt) 2021-05-25
IL237388A0 (en) 2015-04-30
KR101330775B1 (ko) 2013-11-18
BRPI0508410A8 (pt) 2017-03-14
KR20130060360A (ko) 2013-06-07
KR101322433B1 (ko) 2013-10-28
EP1729821A4 (en) 2011-03-16
EP1729821B1 (en) 2013-07-17
MX345724B (es) 2017-02-13
HK1105774A1 (en) 2008-02-22
SG150568A1 (en) 2009-03-30
SG10201803560WA (en) 2018-06-28
SI2656859T1 (sl) 2016-02-29
PT2985039T (pt) 2018-11-09
BRPI0508410B1 (pt) 2017-05-09
SI2985039T1 (sl) 2018-12-31
PT1729821E (pt) 2013-10-23
WO2005084410A9 (en) 2006-03-16
WO2005084410A2 (en) 2005-09-15
IL253007A0 (en) 2017-08-31
EP2985039A1 (en) 2016-02-17
PT2656859E (pt) 2016-02-24
CN102357062B (zh) 2015-08-05
BRPI0508410A (pt) 2007-07-24
HK1185563A1 (en) 2014-02-21
CA2558408A1 (en) 2005-09-15
MXPA06009898A (es) 2008-02-07
TR201815364T4 (tr) 2018-11-21
EP2985039B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
NZ592041A (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2009038779A3 (en) Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
JP2007526340A5 (https=)
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MX2007010673A (es) Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
JP2007526330A5 (https=)
WO2023079142A3 (en) Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EP4501352A3 (en) Compositions and methods for car t cell therapy
NZ593311A (en) Albumin binding peptide-mediated disease targeting
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2008075370A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2011039511A3 (en) Agents, uses and methods
WO2008089491A3 (en) Modifications of peptide compositions to increase stability and delivery efficiency
DE60004172D1 (de) Gcsf konjugate
MX2008011622A (es) Composicion de poliuretano que cura con humedad, con buen desempeƱo a baja temperatura.
MX2009011005A (es) Sellador polimerico para tejido.
WO2011053618A3 (en) Hydroxyl-terminated dendrimers
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
WO1998046270A3 (en) Polymeric conjugates polyvalently presenting an agent for therapy
GB201122325D0 (en) Novel formulations
TW200637836A (en) Cytotoxic agents comprising new taxanes
WO2022026906A3 (en) Lysosomal targeting molecules comprising knottin peptides and related compositions and methods

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 03 MAR 2015 BY SPRUSON + FERGUSON

Effective date: 20130718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2016 BY SKYE DE STE CROIX

Effective date: 20150227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2017 BY CPA GLOBAL

Effective date: 20160226

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2018 BY CPA GLOBAL

Effective date: 20170217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2019 BY CPA GLOBAL

Effective date: 20180303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2020 BY CPA GLOBAL

Effective date: 20190228

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2021 BY THOMSON REUTERS

Effective date: 20200317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2023 BY AJ PARK

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2024 BY THOMSON REUTERS

Effective date: 20230201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 MAR 2025 BY THOMSON REUTERS

Effective date: 20240307

EXPY Patent expired